32results about How to "Sufficient efficacy" patented technology

Illumination devices with improved color mixing optics are disclosed herein for mixing the colors produced by a multi-colored LED emitter module to produce uniform color throughout the entire beam angle of the output light beam, along with smoother edges and improved center beam intensity. Embodiments disclosed herein include a unique arrangement of multi-color LEDs within an emitter module, a unique exit lens with different patterns of lenslets on opposing sides of the lens, and other associated optical features that thoroughly mix the different color components, and as such, provide uniform color across the output beam exiting the illumination device. Additional embodiments disclosed herein include a unique arrangement of photodetectors within the primary optics structure of the LED emitter module that ensure the optical feedback system properly measures the light produced by all similarly colored emission LEDs.

An optical radiation coupling module includes a waveguide for the propagation of optical radiation, an optoelectronic device arranged on a substrate, and a mechanism for coupling the radiation between the waveguide and the optoelectronic device. The coupling mechanism includes a guiding element moulded and tapered in a radiation propagation direction.

The invention relates to an in vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.

A granular pharmaceutical composition for oral administration, wherein a drug-containing particle is coated with a coating comprising a methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymer and a water-soluble polymer is disclosed.

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

A 5α-androstane-3β,5,6β-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-β-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-β-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-β-cyclodextrin solution, 5α-androstane-3β,5,6β-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection.

The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.

A compound represented by the following formula (1):

wherein R¹ is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R² is a C_1-26 hydrocarbon group optionally having substituent(s), R³ is a hydrogen atom or a C_1-26 hydrocarbon group optionally having substituent(s), R⁴ is a C_1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH₂—, and Y is —CH₂—, —CH(OH)— or —CH═CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-γ of NKT cells.

The present invention relates to implantable endoluminal prosthesis for preventing stroke. The endoluminal prosthesis (1) consists of a braided framework (20) defining a cylindrical lumen (21) devoid of impermeable membrane. Said braided framework (20) is self-expandable comprising a plurality of layers (22, 23, 24) of wires (25) made of biocompatible material. Each layer forms a mesh. The meshes form a lattice with a plurality of wires (2) of given layers (22, 23, 24). The lattice defines polygonal opening units (26) when observed normal to a wall of the implantable endoluminal prosthesis (1). The diameter (Ø₂₅) of wire (25) being at least 30 μm and at most 150 μm, the mean diameter (Ø₂₇) of the inscribed circle (27) of the polygonal opening units (26) being at least 75 μm and at most 200 μm in fully expanded state. The braided framework (20) consists of at least 128 and at most 512 wires (25). The ratio (T₁/Ø₂₅) of the thickness (T₁) of a wall of said implantable endoluminal prosthesis (1) to the diameter (Ø₂₅) of wire (25) is at least 3.0. In a fully expanded state, the surface coverage ratio (SCR) of said braided framework (20) is more than 50% and less than 90%.

The present invention relates to a particle having a mean particle size of 0.01 to 20 μm, containing tert-butyl (4R)-4-{[((1R)-2-[(1-benzylpiperidin-4-yl)amino]-1-{[(cyclohexylmethyl)thio]methyl}-2-oxoethyl)amino]carbonyl}-1,3-thiazolidine-3-carboxylate. A preparation containing the particle is excellent in pulmonary delivery through inhalation and is easy to handle because of excellent dispersibility of the particle, and thus the present compound can be used as a pulmonary preparation.

Disclosed is a method for surface treatment of a steel component, providing high resistance to wear and corrosion, including nitriding or nitrocarburising to form a compound layer with a thickness of at least 8 micrometers made up of iron nitrides having phases ε and/or γ′, oxidizing to generate a layer of oxides with a thickness of 0.1-3 micrometers, and soaking in an impregnation bath during at least 5 minutes at room temperature, the bath being made up of at least 70 wt %, ±1%, of a solvent made up of a mixture of hydrocarbons formed by a C9 to C17 alkane fraction, 10 to 30 wt %, ±1%, of at least one paraffin oil formed by a C16 to C32 alkane fraction, and at least one additive such as a synthetic phenolic additive with a concentration of 0.01 to 3 wt %, ±0.1%.

The support member is comprised of a carrier which holds a volatile component. The carrier is comprised of a three-dimensional knitted fabric. The three-dimensional knitted fabric is comprised of a first knitted fabric layer, a second knitted fabric layer, and connecting yarns between them. The connecting yarns connect the first knitted fabric layer with the second knitted fabric layer. At least one knitted fabric layer has a mesh-like structure. A plurality of connecting yarns extend from each stitch of the first knitted fabric layer to each stitch of the second knitted fabric layer and connect each other's stitch. The volatile component is impregnated by the carrier or adhered to the carrier, so that the volatile component is held by the carrier.

Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I):

(where R represents a group represented by the formula: —(CH₂)₄—S—CH₂—CO₂H, —(CH₂)₄—S—CH₂—CO₂CH₃, —(CH₂)₄—C≡C—CO₂H, —CH₂—S—(CH₂)₂—S—CH₂—CO₂H, or —CH₂—S— (CH₂)₄—CO₂H), so that storage stability and content uniformity of the compound of the formula (I) are ensured.